Tekturna Will Track Diovan’s Steady Growth To Blockbuster Status - Novartis

Novartis is hoping sales of its new blood pressure drug Tekturna will climb steadily as morbidity and mortality data amass, eventually leading it to blockbuster status on the same trajectory as top-selling Diovan